10-Q: Autonomix Medical Reports Wider Q3 Loss, Advances Clinical Trials

Autonomix Medical, Inc. reported a significant increase in net loss for the quarter ended September 30, 2025, while advancing its clinical programs and securing new financing agreements.

Summary

• Net loss for the three months ended September 30, 2025, was $7.5 million, compared to $2.8 million for the same period in 2024.
• Net loss for the six months ended September 30, 2025, was $10.8 million, compared to $5.5 million for the same period in 2024.
• Cash and cash equivalents stood at $7.5 million as of September 30, 2025, down from $9.1 million on March 31, 2025.
• Current cash resources are estimated to fund operations into but not beyond the third calendar quarter of 2026.
• An additional $30 million to $36 million in financing is estimated to be required to fund operations to commercialization of its first indication.
• The company completed its initial first-in-human proof-of-concept study (PoC 1) for pancreatic cancer pain with positive clinical outcomes.
• A follow-on study (PoC 2) has been initiated, expanding to include patients with pain from other visceral cancers and earlier-stage pancreatic cancer.
• Stockholders approved a potential reverse stock split (1-for-2 to 1-for-25), an amended 2023 Equity Incentive Plan, and the issuance of more than 20% of common stock under the Lincoln Park Purchase Agreement.
• New patents were issued in the U.S. (cardiology platform, smart torquer device) and Europe (sensing data for real-time physiological monitoring).
• Longer-term post-hoc data from PoC 1 showed a mean pain reduction of approximately 66% and 100% of responders were opioid-free at three months post-procedure.

Sentiment

Score: 3

Explanation: While there are positive clinical and intellectual property developments, the significant increase in net losses, substantial cash burn, short liquidity runway, and explicit going concern warning, coupled with material weaknesses in internal controls, indicate a highly challenging financial position. The positive operational updates are overshadowed by severe financial instability and the need for substantial future capital raises.

Positives

• Successful completion of the initial first-in-human proof-of-concept study (PoC 1) for pancreatic cancer pain with positive clinical outcomes.
• Initiation of a follow-on study (PoC 2) to expand the platform's utility to other visceral cancers and earlier-stage pancreatic cancer patients.
• Strong intellectual property growth with the issuance of a new U.S. patent for cardiology applications and two additional patents (U.S. Patent No. 12,295,646 for a smart torquer device and European Patent No. 3,697,298 for real-time physiological monitoring).
• Positive longer-term post-hoc data from PoC 1 showing a mean pain reduction of approximately 66% and 100% of responders being opioid-free at three months post-procedure.
• Completion of the final design review for the intravascular nerve-sensing catheter, a key step for U.S. clinical studies.
• Secured new financing options, including a $15.0 million purchase agreement with Lincoln Park Capital Fund, LLC and an increase of $1.4 million to the At Market Sales Agreement.

Negatives

• Significant increase in net loss for the three months ended September 30, 2025, to $7.5 million from $2.8 million in the prior year.
• Net loss for the six months ended September 30, 2025, increased to $10.8 million from $5.5 million in the prior year.
• Cash and cash equivalents decreased to $7.5 million as of September 30, 2025, from $9.1 million on March 31, 2025.
• Net cash used in operating activities increased to $6.4 million for the six months ended September 30, 2025, from $3.4 million in the prior year.
• Current cash resources are projected to fund operations only into but not beyond the third calendar quarter of 2026, indicating a short liquidity runway.
• Accumulated deficit reached $61.2 million as of September 30, 2025.
• Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal controls (lack of segregation of duties, general technology controls, financial statement reporting).
• Operating expenses significantly increased, with Research and Development up 102% and General and Administrative up 211% for the three months ended September 30, 2025, primarily due to accelerated stock-based compensation from option cancellations and increased clinical trial costs.

Risks

• Substantial doubt about the company's ability to continue as a going concern within one year due to recurring losses, negative cash flows from operations, and insufficient current capital to reach commercialization.
• Inability to raise additional capital ($30M to $36M estimated) on acceptable terms or at all, which would require scaling back operations.
• The technology remains investigational, with no guarantee of favorable clinical trial outcomes or regulatory approval.
• Significant challenge in scaling from current prototype (hand-assembled, 3D-printed) to a fully integrated commercial-grade device.
• Material weaknesses in internal control over financial reporting, including lack of segregation of duties, general technology controls, and financial statement reporting, which could lead to material misstatements.
• Volatility in the market price of the company's stock and potential dilution to current stockholders from future capital raising activities and equity awards.
• Dependency on third-party manufacturers and ability to obtain all parts required for devices.
• Potential product liability claims.

Future Outlook

The company estimates its current cash resources are sufficient to fund operations into but not beyond the third calendar quarter of 2026. It will need to raise an additional $30 million to $36 million to fund operations to commercialization of its first indication. The company expects to continue incurring significant expenses and operating losses as it advances its technology through development and clinical trials towards regulatory approval.

Management Comments

• We are under no duty to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual results or revised expectations, and we do not intend to do so.
• We believe we have identified material risks, these risks and uncertainties are not exhaustive.
• We are continually monitoring and assessing the situation on our internal controls to minimize the impact on their design and operating effectiveness.
• We believe that the financial statements included in this report fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods presented.

Industry Context

Autonomix Medical operates in the highly competitive and rapidly evolving medical device and life sciences sector, specifically targeting peripheral nervous system disorders. Its focus on a catheter-based solution for pain management, particularly in oncology, positions it within a growing market for minimally invasive therapies. The emphasis on enhanced neural signal detection and real-time processing represents an innovation aimed at improving precision in neuromodulation, a field seeing increasing investment and technological advancement. The expansion of its PoC study to include a broader range of visceral cancers aligns with a trend towards platform technologies addressing multiple indications.

Comparison to Industry Standards

• NA. The filing does not provide specific comparable companies, projects, or results for direct assessment against industry benchmarks. The company is pre-revenue and in early clinical stages, making direct comparisons difficult without external data.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be involved in claims in the ordinary course of business, but currently has no pending material litigation.
• The company does not intend to issue shares for fractional shares related to the Reverse Stock Split and is not currently subject to litigation as a result.

Related Party Transactions

• In August 2025, 54,400 shares of a warrant (issued January 29, 2024, to a company controlled by a significant stockholder) were exercised on a cashless basis for 53,569 shares of common stock. This warrant was issued in exchange for an Exclusive License Termination Agreement from July 7, 2023.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future capital raises (ATM, Lincoln Park agreement, warrant exercises). Potential for reverse stock split to impact share price and perception. Material weaknesses in internal controls pose a risk to financial reporting reliability.
• Employees/Management experienced stock option cancellations and received severance agreements, indicating a restructuring of compensation.
• Investors face high risk due to the going concern warning, substantial losses, and the need for significant future capital. Positive clinical data offers long-term potential but is offset by immediate financial challenges.
• Future customers may benefit from innovative products if commercialization is achieved, but this remains distant and uncertain.
• Creditors face increased financial risk due to the going concern warning and reliance on future capital raises.

Next Steps

• Continue refining catheter design to meet regulatory and manufacturing standards for human use.
• Advance the PoC 2 clinical study, expanding to additional visceral cancers and earlier-stage pancreatic cancer patients.
• Seek regulatory approval for products under development.
• Scale from current prototype to a fully integrated commercial-grade device.
• Raise additional capital (estimated $30M to $36M) to fund operations to commercialization.
• Address material weaknesses in internal control over financial reporting by hiring experienced personnel and upgrading consultants.
• Board of directors to determine the ratio and timing of a potential reverse stock split.

Key Dates

Recommendation

The filing presents a dire financial situation with a clear 'going concern' warning, indicating the company's inability to fund operations beyond Q3 2026 without substantial additional capital. Net losses have more than doubled year-over-year, and cash burn is accelerating. While clinical progress and patent grants are positive, they are severely overshadowed by the company's precarious financial health and material weaknesses in internal controls. The need for $30-36 million in additional financing, coupled with ongoing dilution from existing agreements and a potential reverse stock split, suggests significant downside risk for current shareholders. A seasoned investor would view the high operational burn, limited cash runway, and explicit going concern risk as critical red flags, making the stock a strong sell despite any promising early-stage clinical data.

Keywords

medical device, peripheral nervous system, pancreatic cancer pain, RF ablation, neuromodulation, clinical stage, biotechnology, SEC filing, 10-Q, Autonomix Medical, AMIX, going concern, capital raise, patents, clinical trials, stock split